Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy LM Mir', LF Glass23, G Sersa4, J Teissi65, C Domenge6, D Miklavdid7, MJ Jaroszeski38, S Orlowski9, DS Reintgen38, Z Rudolf4, M Belehradek6, R Gilbertl0, M-P Rols5, J Belehradek Jr', JM Bachaud", R DeConti23, B Stabuc4, M Cemazar4, P Coninx'2 and R Heller38 The application of electric pulses to the patients was safe and well tolerated. An instantaneous contraction of the underlying muscles was noticed. Minimal adverse side-effects were observed. ECT was shown to be an effective local treatment. ECT was effective regardless of the histological type of the tumour. Therefore, ECT offers an approach to the treatment of cutaneous and subcutaneous tumours in patients with minimal adverse side-effects and with a high response rate.
carcinoma
Chemotherapy is a widely used treatment for a broad range of cancers. In many instances, the response rate is low. In melanoma, for example, partial response rates range from 20% to 45%, with complete responses of less than 5% (Buzaid and Murren, 1992; Coates, 1992; Nathanson and Jilani, 1993; Yeung, 1994) . One possible reason for this low response rate is the difficulty of some drugs to cross the cell membrane and reach their intracellular site of action. The application of short and intense electric pulses can reversibly permeabilize membranes of all living cells, including mammalian, bacterial, yeast and plant cells Neumann et al, 1989; Rols and Teissie, 1990; Orlowski and Mir, 1993) . These electric pulses have been used in vitro to introduce drugs, foreign DNA and other exogenous molecules into cells .
Bleomycin is a very potent cytotoxic molecule when introduced inside the cell. A few hundred molecules are sufficient to be cyto-toxic (Poddevin et al, 1991; Tounekti et al, 1993) . However, bleomycin does not freely diffuse through the plasma membrane and has very limited access to the cytosol (Orlowski et al, 1988; Poddevin et al, 1991) . Bleomycin normally enters cells through interaction with a membrane protein that mediates its internalization . Response is a function of the presence or absence of this membrane protein . This could be a significant reason why bleomycin has had limited success as an anti-tumour agent. Electropermeabilization of cells as well as tissues allows bleomycin to enter the cytosol directly and to exert fully its cytotoxic potential (Orlowski et al, 1988; Poddevin et al, 199 1; Tounekti et al, 1993; Belehradek et al, 1994) . Therefore, bleomycin is an excellent candidate for combining with electric pulses because it is non-permeant and at the same time highly cytotoxic once inside the cell.
The anti-tumour effectiveness of bleomycin was shown to be greatly increased by the local delivery of permeabilizing electric pulses at the tumour in preclinical trials with mice Mir et al, 1991) . The permeabilizing effect is restricted to an area encompassed by the electrodes. Electric pulses delivered after the administration of bleomycin actually increased drug delivery to tumours . However, electric pulses delivered alone did not elicit an anti-tumour response. Anti-tumour effects were observed in many different animal models Salford et al, 1993; Mir, 1994; Ser'sa et al, 1994; 1995; Yamaguchi et al, 1994; Cemazar et al, 1995; Heller et al, 1995) . Anti-tumour treatment with this combined therapy can be used in tumour systems in which bleomycin alone was not typically used . This new anti-tumour therapy that combines the administration of a non-permeant drug such as bleomycin with local permeabilizing electric pulses was termed electrochemotherapy (ECT) Mir, 1994) . The principle of ECT is characterized by a more efficient manner of drug delivery that increases the effectiveness of the administered drug with reduced side-effects.
The first ECT clinical trial performed in Villejuif, France, treated cutaneous nodules of metastatic squamous cell carcinoma present on the head and neck . Objective responses were obtained in 72% of 40 treated nodules in eight patients. The therapy was well tolerated by the patients. Preliminary sedation 1 h before ECT or in one case short neuroleptanalgesia was used. Subsequently, several clinical trials have been initiated in other cancer centres. Preliminary reports of these trials on 15 patients have been published (Heller, 1995; Rudolf et al, 1995; Domenge et al, 1996) . Patients with basal cell carcinoma, malignant melanoma, adenocarcinoma or squamous cell carcinoma were enrolled in these trials to determine if ECT is applicable to tumours of other histological types. All trials used bleomycin, which was administered several minutes before delivery of electric pulses. This report presents a summary of results obtained from clinical trials performed independently in five cancer centres and included the treatment of 291 tumours in 50 patients.
PATIENTS AND METHODS Patients and inclusion criteria
Ten patients with basal cell carcinoma (BCC), 20 with metastatic malignant melanoma, three with adenocarcinoma of the salivary gland or breast and 17 with head and neck squamous cell carcinoma (HNSCC) were entered in trials initiated in five different cancer centres. These were located in Villejuif (VI), Toulouse (TO), Reims (RE) 
Protocols for electric pulse delivery
Treatment included applying rectangular-wave electric pulses directly to tumours after bleomycin administration. The French and Slovenian centres (VI, RE, TO and LJ) used electrodes that consisted of two stainless steel strips 10 mm wide and 0.6 mm thick. Insulating material was used to maintain a fixed gap between the two strips. Spacing between the electrodes was 7 mm for VI, RE and LJ and 6 mm for TO. Electric pulses were delivered by a PS 15 electropulsator (Jouan, Nantes, France) that was designed to obey the electric current limits set by the European Community (Commission for Industrial Electricity, 1984) . The US centre (TA) used electrodes consisting of two stainless steel squares of 20 mm mounted on a vernier caliper or a circular array of six needles. The caliper-mounted electrodes allowed the gap to be adjusted according to the size of the tumour and the needle array electrode was fixed at a 10 mm diameter. Electric pulses were delivered by a BTX T820 generator (Genetronics, San Diego, CA, USA). aBleomycin dose and route of administration; i.v., intravenous; i.t., intratumour. bElectric pulses -number of electric pulses administered to each treated tumour.
cTumours located in areas poorly perfused by blood as indicated in text. dPatient treated in two sessions. eSame tumours treated in two sessions. fNot the whole tumour area was treated. gPatient treated in three sessions. cOwing to the time required to treat the large tumours, a supplement of bleomycin was administered. dTumours were non-evaluable because of too short follow-up.
Either four, six or eight electric pulses were delivered per treatment site by placing electrodes on the skin adjacent to the tumour. Electric pulses were delivered at a rate of one pulse per second. All the patients treated in VI, TO, RE and LJ received either four or eight electric pulses. In LJ this was accomplished by delivering four pulses then rotating the electrodes 900 and administering four additional pulses. This is denoted as a 4+4 configuration . Patients treated in TA received either eight (caliper electrodes) or six (needle array electrode) electric pulses. The ratio of voltage to electrode distance was 1300 V cm-' for all teams, (Table 4 ). All of these were found to be CRs. Eight additional metastatic nodules were treated but could not be evaluated because of a too short follow-up period. The two control nodules receiving bleomycin alone had PD.
Head and neck squamous cell carcinoma
Objective responses were seen in 48 (62.3%) of the 77 HNSCC evaluable nodules ( 1 7 patients) treated (Table 5) . Of these nodules, 33 (42.8%) were in CR and 15 (19.5%) in PR. Only eight (10.3%) of the nodules were PDs. Ten additional nodules were not evaluated because of too short follow-up of the patient. On a per patient basis, we obtained two CRs ( 12%) and four PRs (24%). In the case of the HNSCC nodules, it was necessary to distinguish between nodules that could be encompassed with one treatment using transcutaneous electric pulses and the very large nodules treated with sequential electrical treatments. The treatment of the large nodules was important for the determination of some parameters and constraints of electrochemotherapy. For these large nodules, massive necrosis and reduction in the height of the nodule was observed but, as expected, the deepest parts were not completely affected by ECT, presumably because they were not crossed by an electric field of sufficient intensity.
Tolerance during and after the treatment No significant modification of haemodynamic or cardiological parameters was noticed during ECT. A contraction of muscles located beneath the site of treatment was observed. The contractions were instantaneous, disappearing immediately after the end of each electric pulse (1/10 000th of a second in length). Several procedures, either local or systemic, as described above, were used for relief of the sensations that accompanied the contractions. General anaesthesia seems more appropriate when large and/or multiple nodules are treated, whereas local anaesthesia would be sufficient for the treatment of a few small tumours.
Erythema and slight oedema at the site of the treated areas were the only noticeable symptoms observed transiently and remained less than 24 h. Transient marks from electrodes were also often visible after ECT. Superficial leuconecrosis was observed in the case of the large tumours for which the skin was already altered before ECT. For patients receiving only sedatives or local anaesthesia, some pain was involved during the procedure, which subsided immediately after the last pulse was delivered. All patients agreed that it was tolerable and they would undergo the procedure again. As a matter of fact, several patients returned for treatment of additional lesions. In addition, no delayed pain was reported by the patients. In several cases, the pain associated with the tumour was attenuated after ECT. No enhanced systemic bleomycin toxicity was observed.
DISCUSSION
Results reported here from five cancer centres included the treatment of 273 evaluable tumours with an objective response rate of 85.3%. ECT was safe and well tolerated by the patients. The high rate of objective responses was obtained regardless of the histological type of the treated tumours. These results are encouraging for the future development of ECT and illustrate that ECT has the potential to be a potent anti-tumour treatment even when the treatment protocol is varied.
The high rate of objective responses obtained regardless of histological type is in agreement with the fundamental basis of ECT. Cell electropermeabilization is a universal phenomenon occurring in all types of living cells and results from the interaction of electric fields with a low conductive membrane composed of lipids and proteins (Neumann et al, 1989; Orlowski and Mir, 1993) . Once inside the cell, interaction of bleomycin with DNA results in a chemical reaction that generates highly cytotoxic DNA double-strand breaks (Poddevin et al, 1991; Tounekti et al, 1993) . Thus, all histological types of tumours should be sensitive to ECT.
Electric pulses have to be delivered during the period for which the interstitial bleomycin concentration in the tumour is sufficient. This period was determined in one of the clinical situations examined (HNSCC) to be from 8 to 28 min after bleomycin i.v. bolus injection. This time frame is perhaps longer if bleomycin is injected slowly (for example at a rate of 1.5 units min-'). However, the concentration of bleomycin at the treatment site is probably lower. Although there is a defined window of opportunity for successful treatment when administering bleomycin i.v., this does not present a problem because the procedure for applying electric pulses is very rapid (4-8 s) and can be repeated many times inside the therapeutical window in the case of very large tumours or several tumours.
An alternative procedure to i.v. bleomycin administration is i.t. injection, which proved to be effective as well. Moreover, if tumour treatment is associated with a local approach for analgesia, then every tumour can be treated independently, and the whole ECT session can be split in as many partial sessions as required. The results found in these studies indicate that ECT is an effective treatment irrespective of the bleomycin administration route. Therefore, the treatment can be administered in a variety of ways depending on the clinical situation.
An important observation was that ECT was safe and resulted in minimal side-effects. In particular, no significant modification of the haemodynamic or cardiological parameters was noticed even when the treated tumours were located in the chest above the cardiac region. However, there is a contraction of the muscles located beneath the electrodes as the muscle cells are excited by the electric pulses. Many patients had disagreeable sensations associated with the delivery of electric pulses. This was short lived and disappeared immediately after pulsing. In addition, sometimes transient marks from the electrodes were visible.
Thus, at the present time, ECT can already be considered as an effective treatment, whatever the histological type of the tumour. ECT has been efficient on multiple BCCs in patients previously disfigured by surgery who refused further surgery. Scarring was minimal in the treated sites, which makes ECT an obvious advantage over a surgical excision. ECT was also effective as a local treatment for malignant melanoma with a 92.2% objective response. ECT has also proven anti-tumour effectiveness on otherwise untreatable HNSCC nodules as these nodules, resistant to conventional chemotherapy, were located in areas previously treated by surgery and radiotherapy. An important observation was that results were consistent among the different centres even though the procedure was varied. This highlights that the basic premise of ECT, permeabilization of tumour cells in the presence of a chemotherapeutic agent, is the key to successful therapy. Thus, the most appropriate chemotherapeutic agent for this kind of treatment is not the usual appropriate drug for each specific situation but a non-permeant drug (such as bleomycin) for which the cytotoxicity will be highly potentiated by tumour cell electropermeabilization, whatever the carcinological situation.
ECT has been demonstrated to be an effective local treatment that can be added to the usual set of local anti-cancer therapies. For the treatment of metastatic diseases it is important to add a systemic component to ECT. Therefore, in preclinical trials, ECT has been combined with immunotherapy. Systemic effect demonstrated by responses of distant tumours was obtained by combining local ECT with the local administration of histoincompatible interleukin 2 (IL-2)-secreting cells in a murine model (Mir et al, 1995) . In addition, local anti-tumour effect was enhanced by the local administration of IL-2 (Mir et al, 1992) . Thus, the combination of ECT with immunotherapy may lead to a wider applicability of the technique by producing a systemic anti-tumour treatment.
New possibilities of ECT are presently being explored in preclinical trials with the use of cisplatin. Although cisplatin is a more permeant drug than bleomycin its effectiveness was also augmented by electropermeabilization of cells in vitro as well as tumours in vivo . Cisplatin is currently used in many chemotherapeutic protocols. Therefore, ECT with cisplatin can be useful in patients as an adjuvant to ongoing cisplatin treatment. These results are encouraging and suggest that the effectiveness of other anti-tumour agents may also be augmented by electropermeabilization.
